Back to search
Scientific Name: Cobimetinib
Brand Name: Cotellic
Company Owner: Not Available
Mechanism Of Action Cobimetinib is a reversible inhibitor of mitogen-activated protein kinase (MAPK) /extracellular signal-regulated kinase 1 (MEK1) and MEK2. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. BRAF V600E and K mutations result in constitutive activation of the BRAF pathway which includes MEK1 and MEK2. In mice implanted with tumor cell lines expressing BRAF V600E, cobimetinib inhibited tumor cell growth.
Description of the Drug: Cobimetinib is an antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway used to treat unresectable or metastatic melanoma.
Protein Data Bank:
Source: DrugBank Online – Retrieved 2023-01-23 from